Venus Remedies Ltd informed that the company's IPR department has filed its 7th patent application with the Indian Patent Office for a novel, safe, low chose, non - irritating, highly efficacious and physiologically compatible antibiotic for the treatment of bacterial / multi-bacterial infections in children.

The Patent titled "A Low Dose Combination Anti-biotic Formulation" is a novel treatment developed at Venus Medicine research centre. This formulation, a fixed dose combination of a latest generation Carbapenem and a latest generation Amino-glycoside, will be the best available solution for treatment of multi-bacterial infections in Neo-Natals and children being 4-8 times more effective at the lowest possible dosage levels - approximately 83 per cent reduction in dosage from conventional therapies-, minimal ototoxicity and nephrotoxicity among all available known similar treatments world wide till date.

The WHO estimates that one in three infant deaths worldwide occur due to pneumonia (approx 13 million each year) and the mortality rate in bacterial meningitis is approximately 20 per cent in children. This new FCC is highly effective against the cephalosporin resistant gram negative aerobic bacilli as well as the penicillin resistant pneumonococci including enterobacteria species, klebsiella pneumoniae, pseudomonas aeruginosa, streptococcus pneurnoniee, MRSA, haemophllus influenza, neisseria meningitides (meningococcus), and highly effective for treatment of infections in immuno-compromised patients.